Febhuwari 2024: I-Mesenchymal stem cell (MSCs) kanye nokwelashwa kwe-plasma ecebile nge-platelet (PRP) kubonise amandla ekwelapheni i-knee osteoarthritis (KOA) e-China. Ukuhlaziywa kwemeta yezifundo ezilawulwa ngokungahleliwe kubheke ekusebenzeni nokuphepha kwama-MSC axutshwe ne-PRP ekwelapheni i-KOA. Ucwaningo luthole ukuthi inhlanganisela yama-MSC kanye ne-PRP yayisebenza kahle emtholampilo ekwehliseni izinhlungu nokusebenza okuhlangene ezigulini ze-KOA. Lokhu kwelashwa akubanga nomehluko omkhulu ezimpendulweni ezimbi uma kuqhathaniswa nama-MSC kuphela.
Abacwaningi baseShayina baphinde baphenya ngokusetshenziswa kwamaseli we-autologous bone mesenchymal stem cell ahlanganiswe ne-platelet-rich plasma ekwelapheni i-knee osteoarthritis, nemiphumela ethembisayo. Ngaphezu kwalokho, ucwaningo luye lwabheka ukusebenza kahle kwamangqamuzana e-mesenchymal stem atholakala egazini ahlanganiswe ne-plasma ecebile ehlanganiswe ne-platelet ekwelapheni i-knee osteoarthritis.
Ukwelashwa kwe-plasma okucebile nge-Platelet bekulokhu kusetshenziselwa ukwelapha i-osteoarthritis yamadolo, nedatha esekela ukusebenza kwayo ngempumelelo. I-PRP iqukethe izici zokukhula ezikhuthaza ukulungiswa nokuvuselelwa kwezicubu, okwenza kube ingxenye ebalulekile ekwelapheni i-osteoarthritis.
Finally, the combination of mesenchymal stem cells and platelet-rich plasma therapy shows promise for reducing pain, joint function, and tissue healing in Chinese knee osteoarthritis patients. Additional research and izivivinyo zokwelashwa are required to validate and optimize this therapeutic strategy.
Ungahle uthande ukufunda: Ukwelashwa kwe-CAR T-Cell eChina
Iyini i-mesenchymal stem cell therapy futhi isebenza kanjani?
Ukwelashwa kwe-Mesenchymal stem cell (MSC) kusebenzisa ama-stem cells amadala angakhula abe amaseli amathambo, uqwanga, imisipha, nama-fat. Ama-MSC abalulekile ekwelashweni kokuvuselelayo ngoba angakwazi ukuzivuselela futhi ahlukanise abe imigqa eminingi. Lawa maseli angatholakala kumnkantsha wamathambo, izicubu ze-adipose, noma izicubu zenkaba.
Ama-MSC anamandla okuvikela amasosha omzimba, okusho ukuthi angalawula ukusebenza kwamasosha omzimba, ehlise ukuvuvukala, futhi acindezele izimpendulo ze-immunological. Lesi sici sizenza zibe namandla ekwelapheni ukuphazamiseka kwe-autoimmune kanye nokwenqatshwa kokufakelwa. Ama-MSC angakwazi futhi ukusekela ukulungiswa kwezicubu nokuvuselelwa kabusha ngokukhulula izici zokukhula nama-cytokines, aheha amanye amaseli endaweni yomonakalo futhi akhuthaze ukuthuthukiswa kwemithambo yegazi emisha edingekayo ukuze kulungiswe izicubu.
Ukusebenza kahle kokwelapha kwama-MSC kunqunywa amandla awo okuthuthela endaweni elimele, ukunamathela, kanye nokugxiliswa kusicubu esiqondiwe. Ama-MSC ikakhulukazi awawona ama-immunogenic ngenxa ye-immunophenotype yawo, okuwenza alungele ukwelashwa okusekelwe kumaseli ezifweni ezihlukahlukene.
Nakuba ukwelapha kwe-MSC kubonise isithembiso ezifundweni zangaphambi komtholampilo zokwelapha izifo ezifana ne-osteogenesis imperfecta, Isifo sika-Crohn, i-Multiple Sclerosis, i-Parkinson's, nezinye, ucwaningo olwengeziwe luyadingeka ukuze kubambe ngokugcwele amandla azo futhi kukhiqizwe imithi ephephile nesebenzayo. Ukuqinisekisa ukusetshenziswa okuphephile nokuphumelelayo kokwelashwa kwe-MSC emithini evuselelayo, kubalulekile ukubhekana kokubili izinzuzo zayo kanye nemikhawulo engaba khona.
Ungahle uthande ukufunda: I-CAR T Cell therapy ye-myeloma eminingi e-China
Yiziphi izinhlobo ezahlukene ze-mesenchymal stem cell?
I-Mesenchymal stem cells (MSCs) ama-stem cells amadala akwazi ukuzivuselela futhi ahlukanise abe izinhlobo zamaseli ezihlukahlukene. Ama-MSC ahlukaniswa ngezigaba ezahlukahlukene ngokuya ngezicubu zawo zemvelaphi, ngayinye inesethi yayo yezici kanye nezinhlelo zokusebenza:
1. Amaseli we-mesenchymal stem cell asuselwa kumnkantsha (BMSCs): Lawa maseli atholakala kakhulu emnkantsheni futhi aphenywe kabanzi mayelana namandla awo okuvuselela. Amaseli we-bone marrow stem angahlukanisa abe amathambo, uqwanga, izicubu ze-adipose, imisipha, nezinye izinhlobo zamaseli.
2. Amaseli we-mesenchymal stem asuselwa kuzicubu ze-Adipose (ADSCs): Ama-ADSC asuselwa kuzicubu ze-adipose futhi anezimfanelo ezifanayo kuma-BMSC. Angakwazi ukwehlukanisa abe izinhlobo zamaseli amaningi, awenze abe usizo ezinhlelweni zokwelashwa ezivuselelayo.
3. Amaseli Esiqu Se-Umbilical-Derived Mesenchymal Stem (UC-MSCs): Ama-UC-MSC asuselwa kuzicubu zenkaba futhi abonise imiphumela ekhuthazayo ezifundweni. Lawa maseli anekhono lokuhlukanisa imigqa eminingi futhi angathuthuka abe amathambo, uqwanga, umsipha, nezinye izinhlobo zamaseli.
Uhlobo ngalunye lwe-MSC lunezici nezinzuzo ezihlukile, okulwenza lusebenziseke ezinhlobonhlobo zezinhlelo zokwelapha. Ama-MSC anamandla amakhulu ekwelapheni okuzivuselelayo ngenxa yekhono lawo lokuhlukanisa abe izinhlobo eziningi zamaseli namandla awo okuvikela umzimba. Ucwaningo olwengeziwe luyenziwa ukuze kutholwe amandla aphelele okwelapha ezinhlobo ezehlukene zama-MSC ekwelapheni inhlobonhlobo yezifo neziyaluyalu.
Iyini imiphumela emibi ye-mesenchymal stem cell (MSC) kanye ne-platelet-rich plasma (PRP) yokwelapha?
I-Mesenchymal stem cell (MSC) kanye nokwelashwa kwe-platelet-rich plasma (PRP) kubonise isithembiso ekwelapheni izifo ezihlukahlukene, kodwa kubalulekile ukuhlola imiphumela emibi engaba khona. Ngokocwaningo, inhlanganisela yama-MSC kanye ne-PRP ekwelapheni i-knee osteoarthritis ibonise ukusebenza kahle komtholampilo mayelana nokukhululeka kobuhlungu nokusebenza kwamalunga, kungekho mehluko omkhulu emiphumeleni emibi uma iqhathaniswa nama-MSC kuphela.
Nakuba i-PRP ibonise ukuphepha okuhle nokusebenza ngempumelelo ekwelapheni i-knee osteoarthritis, inzuzo yokwelapha ingase yehle njengoba iminyaka yesiguli ikhula. Ngaphezu kwalokho, ucwaningo luye lwabonisa ukuthi i-PRP ingashukumisa ukwanda nokuhlukaniswa kwama-MSC, angasiza ekwelapheni kwezicubu. Nokho, kubalulekile ukukhumbula ukuthi imiphumela engemihle ehlobene nomjovo, njengokungakhululeki, ukulimala kwezinzwa, nokushintsha kombala kwesikhumba, ingenzeka kodwa ayivamile.
Ngaphezu kwalokho, lapho kuhlolwa umthelela wama-MSC kanye nokwelashwa kwe-PRP ekwelapheni kwesilonda esicucu, kubalulekile ukuhlola ukubukeka kwamangqamuzana nokusebenza kwayo kwawonke ukuze kugwenywe imiphumela engemihle kanye nokulindelwe okungenangqondo ekwelapheni kwamaseli. Ukuhlolwa okufanele nokuqonda umsuka wamangqamuzana asetshenziswa ekwelapheni kungasiza ekunciphiseni imiphumela engemihle.
Sengiphetha, nakuba ama-MSC kanye nokwelashwa kwe-PRP kunamandla okuzuzisa izimo ezihlukahlukene, okuhlanganisa ukuphulukiswa kwesilonda kanye ne-osteoarthritis, kubalulekile ukuqaphela imiphumela engemihle engase ibe khona futhi uqinisekise ukuhlolwa nokuqapha okufanele ukuze kwandiswe ukusebenza kahle kwazo kuyilapho unciphisa izingozi.
Zithini izindleko ze-MSC ne-PRP ze-knee osteoarthritis e-China?
Ukwelashwa okuhlangene kwe-MSC kanye ne-PRP ye-knee osteoarthritis e-China kuzobiza cishe u-$7000 USD futhi amazwe amabili azobiza cishe u-$12000 USD.
